You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

dMMR

Showing 151 - 169 of 169
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cervical Cancer Trial (BAVC-C+Durvalumab)

Not yet recruiting
  • Cervical Cancer
  • BAVC-C+Durvalumab
  • (no location specified)
Mar 14, 2021

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Seoul (Docetaxel, Oxaliplatin, S-1 and Durvalumab,

Recruiting
  • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
  • Docetaxel, Oxaliplatin, S-1 and Durvalumab
  • Durvalumab and Tremelimumab
  • Seoul, Korea, Republic of
    Asan Medical Center
Jun 1, 2020

Rectal Cancer, Rectal Adenocarcinoma, Rectal Tumors Trial (Durvalumab, FOLFOX, Short Course Radiotherapy (Arm A))

Not yet recruiting
  • Rectal Cancer
  • +2 more
  • (no location specified)
Nov 6, 2020

Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma Trial in

Recruiting
  • Endometrial Clear Cell Adenocarcinoma
  • +17 more
  • Birmingham, Alabama
  • +376 more
Aug 24, 2022

Advanced Solid Tumor,Recurrent Solid Tumor,Lymphoma,Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma Trial in Linyi

Unknown status
  • Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
  • Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
  • Linyi, Shandong, China
    Shaohong Yin
Oct 19, 2020

Tumors, Colorectal Cancer Trial in Grand Rapids, Nashville, Kirkland (MK-8353, Pembrolizumab)

Completed
  • Neoplasms
  • Colorectal Cancer
  • Grand Rapids, Michigan
  • +2 more
Dec 21, 2022

Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content, Head Neck Cancer Squamous Cell Carcinoma, NSCLC Trial in

Recruiting
  • Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
  • +12 more
  • Palo Alto, California
  • +9 more
Mar 24, 2022

Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable Trial in France (Capecitabine, Oxaliplatin,

Recruiting
  • Colorectal Cancer Metastatic
  • +2 more
  • Abbeville, France
  • +87 more
Mar 23, 2022

Recurrent Endometrial Cancer Trial (Pembrolizumab, Axitinib)

Withdrawn
  • Recurrent Endometrial Cancer
  • (no location specified)
Nov 4, 2020

Solid Tumor, Lymphoma Trial in Chicago, Morristown (Ad-p53)

Unknown status
  • Solid Tumor
  • Lymphoma
  • Chicago, Illinois
  • +2 more
Jun 5, 2020

Rectal Tumors Malignant Trial in China (Transanterior obturator nerve gateway approach, Total mesorectal excision approach)

Enrolling by invitation
  • Rectal Neoplasms Malignant
  • Transanterior obturator nerve gateway approach
  • Total mesorectal excision approach
  • Baotou, Inner Mongolia, China
  • +3 more
Oct 4, 2021

Clinical and Biological Analysis of Exocrine Pancreatic Tumors

Not yet recruiting
  • Exocrine Pancreatic Cancer
    • (no location specified)
    Feb 4, 2020

    Colorectal Cancer Trial in Guangzhou (JS001, regorafenib tablet)

    Unknown status
    • Colorectal Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 11, 2020

    Castration-Resistant Prostatic Cancer Trial (Whole Exome Sequencing)

    Not yet recruiting
    • Castration-Resistant Prostatic Cancer
    • Whole Exome Sequencing
    • (no location specified)
    Nov 3, 2019

    Screening of Hereditary Upper Gastrointestinal Cancer in China

    Unknown status
    • Improve the Screening Criteria of Chinese Hereditary Upper Gastrointestinal Tumors
    • Gene detection
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jun 2, 2019

    MMR Status and PD-L1 Expression Using Specimens Obtained by

    Unknown status
    • Pancreatic Cancer
    • EUS-FNB
    • Immunohistochemistry
    • (no location specified)
    Jan 27, 2019

    Endometrial Cancer Stage I Trial (PD-1 inhibitor combined progesterone, progesterone)

    Unknown status
    • Endometrial Cancer Stage I
    • (no location specified)
    Aug 5, 2019

    Gastrointestinal Cancer Trial in Shenyang (Next generation sequencing)

    Unknown status
    • Gastrointestinal Cancer
    • Next generation sequencing
    • Shenyang, Liaoning, China
      The First Affiliated Hospital of China Medical University
    Apr 12, 2019

    NSCLC, Carcinoma, Renal Cell, Breast Tumors Trial in United States (SGN-2FF, pembrolizumab)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • +7 more
    • Birmingham, Alabama
    • +10 more
    Jul 17, 2019